{
    "clinical_study": {
        "@rank": "97260", 
        "arm_group": {
            "arm_group_label": "TIM-3", 
            "arm_group_type": "Experimental", 
            "description": "T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity."
        }, 
        "brief_summary": {
            "textblock": "This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing\n      molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with\n      Crohn's disease during anti TNF-\u03b1 (infliximab) therapy."
        }, 
        "brief_title": "Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-\u03b1 Therapy", 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "The immunoregulatory effects of TIM-3 on patients with Crohn's disease according to the\n      treatment have not yet been investigated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022Pediatric patients who were diagnosed with severe Crohn's disease who require\n             infliximab treatment\n\n               -  confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological\n                  findings\n\n        Exclusion Criteria:\n\n          -  \u2022patients who has proven to have infliximab antibody"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "17 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661257", 
            "org_study_id": "2009-10-038-002"
        }, 
        "intervention": {
            "arm_group_label": "TIM-3", 
            "intervention_name": "Infliximab", 
            "intervention_type": "Drug", 
            "other_name": "Remicade"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies", 
                "Infliximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's disease", 
            "Infliximab", 
            "T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3)"
        ], 
        "lastchanged_date": "August 7, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Expression of T-cell Immunoglobulin- and Mucin-domain-containing Molecule 3 (TIM-3)and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-\u03b1 Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Disease Activity Index (PCDAI) scores, Peripheral blood for TIM-3 mRNA expression", 
            "measure": "Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease with anti TNF-\u03b1 Therapy", 
            "safety_issue": "No", 
            "time_frame": "1-year treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661257"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "YonHo Choe", 
            "investigator_title": "Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2009", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}